药物性肝损伤慢性化的研究近况

黄昂; 孙颖; 邹正升

doi:10.3969/j.issn.1001-5256.2020.03.004

药物性肝损伤慢性化的研究近况

DOI: 10.3969/j.issn.1001-5256.2020.03.004

解放军总医院第五医学中心非感染性肝病诊疗与研究中心

基金项目:

国家自然科学基金(81600453)；临床试验(注册号NCT02651350)；北京市科技新星计划(Z171100001117114)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1175
- HTML全文浏览量: 51
- PDF下载量: 349
- 被引次数: 0
出版历程
- 出版日期: 2020-03-20

Recent research advances in chronicity of drug-induced liver injury

Treatment and Research Center for Non-infectious Liver Diseases, The Fifth Medical Center of Chinese PLA General Hospital

Research funding:

摘要

摘要: 尽管药物性肝损伤(DILI)通常表现为急性过程,但仍有约20%患者会发生慢性化。慢性DILI病程反复且无有效﹑公认的治疗方法。随着新药的不断研发及其临床应用,以及中药和食物补充剂的应用,DILI慢性化的发生率不断增高。通过DILI流行病学﹑危险因素﹑临床表现﹑诊断及治疗等角度对DILI慢性化的最新研究近况进行概述,以期更加全面地了解认识慢性DILI。
- 药物性肝损伤 /
- 慢性病 /
- 诊断 /
- 治疗学
Abstract: Although drug-induced liver injury( DILI) is often an acute process,about 20% of the patients may progress to chronic DILI.Chronic DILI has a long course of disease and there is still no effective treatment. With the development and clinical application of new drugs and the wide application of herbal and dietary supplements,the incidence rate of DILI chronicity gradually increases. This article overviews the latest research advances in DILI chronicity from the aspects of the epidemiology,risk factors,clinical manifestations,diagnosis,and treatment of DILI,so as to gain a comprehensive understanding of chronic DILI.
- drug-induced liver injury /
- chronic disease /
- diagnosis /
- therapeutics

HTML全文

参考文献(25)

[1] MEDINA-CALIZ I,ROBLES-DIAZ M,GARCIA-MUNOZ B,et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury[J]. J Hepatol,2016,65(3):532-542.

[2] CHANG B,LI B,HUANG A,et al. Changes of four common non-infectious liver diseases for the hospitalized patients in Beijing 302 hospital from 2002 to 2013[J]. Alcohol,2016,54:61-65.

[3] FONTANA RJ,HAYASHI PH,GU J,et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset[J]. Gastroenterology,2014,147(1):96-108,e4.

[4] CHALASANI N,FONTANA RJ,BONKOVSKY HL,et al. Causes,clinical features,and outcomes from a prospective study of drug-induced liver injury in the United States[J]. Gastroenterology,2008,135(6):1924-1934.

[5] ANDRADE RJ,LUCENA MI,KAPLOWITZ N,et al. Outcome of acute idiosyncratic drug-induced liver injury:Long-term follow-up in a hepatotoxicity registry[J]. Hepatology,2006,44(6):1581-1588.

[6] AITHAL GP,WATKINS PB,ANDRADE RJ,et al. Case definition and phenotype standardization in drug-induced liver injury[J]. Clin Pharmacol Ther,2011,89(6):806-815.

[7] Drug-Induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组．药物性肝损伤诊治指南[J]．临床肝胆病杂志，2015,31(11):1752-1769.

[8] AITHAL PG,DAY CP. The natural history of histologically proved drug induced liver disease[J]. Gut,1999,44(5):731-735.

[9] BJÖRNSSON E,KALAITZAKIS E,AV KLINTEBERG V,et al.Long-term follow-up of patients with mild to moderate drug-induced liver injury[J]. Aliment Pharmacol Ther,2007,26(1):79-85.

[10] SHEN T,LIU Y,SHANG J,et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology,2019,156(8):2230-2241. e11.

[11] FONTANA RJ,HAYASHI PH,BARNHART H,et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury[J].Am J Gastroenterol,2015,110(10):1450-1459.

[12] CHALASANI N,BONKOVSKY HL,FONTANA R,et al. Features and outcomes of 899 patients with drug-induced liver injury:The DILIN prospective study[J]. Gastroenterology,2015,148(7):1340-1352. e7.

[13] BJÖRNSSON E,DAVIDSDOTTIR L. The long-term followup after idiosyncratic drug-induced liver injury with jaundice[J]. J Hepatol,2009,50(3):511-517.

[14] FONTANA RJ,SEEFF LB,ANDRADE RJ,et al. Standardization of nomenclature and causality assessment in drug-induced liver injury:Summary of a clinical research workshop[J]. Hepatology,2010,52(2):730-742.

[15] KLEINER DE,CHALASANI NP,LEE WM,et al. Hepatic histological findings in suspected drug-induced liver injury:Systematic evaluation and clinical associations[J]. Hepatology,2014,59(2):661-670.

[16] REUBEN A,KOCH DG,LEE WM,et al. Drug-induced acute liver failure:Results of a U. S. multicenter,prospective study[J]. Hepatology,2010,52(6):2065-2076.

[17] ROBLES-DIAZ M,LUCENA MI,KAPLOWITZ N,et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury[J]. Gastroenterology,2014,147(1):109-118. e5.

[18] LUCENA MI,KAPLOWITZ N,HALLAL H,et al. Recurrent druginduced liver injury(DILI)with different drugs in the Spanish Registry:The dilemma of the relationship to autoimmune hepatitis[J]. J Hepatol,2011,55(4):820-827.

[19] AMACHER DE,CHALASANI N. Drug-induced hepatic steatosis[J]. Semin Liver Dis,2014,34(2):205-214.

[20] DANIEL F,CADRANEL JF,SEKSIK P,et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients[J].Gastroenterol Clin Biol,2005,29(5):600-603.

[21] CROCETTI D,PALMIERI A,PEDULLA G,et al. Peliosis hepatis:Personal experience and literature review[J]. World J Gastroenterol,2015,21(46):13188-13194.

[22] SEBODE M,SCHULZ L,LOHSE AW．“Autoimmune(-Like)”drug and herb induced liver injury:New insights into molecular pathogenesis[J]. Int J Mol Sci,2017,18(9). pii:E1954.

[23] BONKOVSKY HL,KLEINER DE,GU J,et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements[J]. Hepatology,2017,65(4):1267-1277.

[24] LIN G,WANG JY,LI N,et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum[J]. J Hepatol,2011,54(4):666-673.

[25] CHALASANI NP,HAYASHI PH,BONKOVSKY HL,et al. ACG clinical guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol,2014,109(7):950-966; quiz 967.

施引文献

资源附件(0)

访问统计